Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
M Gary-Bobo, G Elachouri, JF Gallas, P Janiak… - Hepatology, 2007 - journals.lww.com
This study investigated the effects of rimonabant (SR141716), an antagonist of the
cannabinoid receptor type 1 (CB1), on obesity-associated hepatic steatosis and related
features of metabolic syndrome: inflammation (elevated plasma levels of tumor necrosis
factor alpha [TNFα]), dyslipidemia, and reduced plasma levels of adiponectin. We report that
oral treatment of obese (fa/fa) rats with rimonabant (30 mg/kg) daily for 8 weeks abolished
hepatic steatosis. This treatment reduced hepatomegaly, reduced elevation of plasma levels …
cannabinoid receptor type 1 (CB1), on obesity-associated hepatic steatosis and related
features of metabolic syndrome: inflammation (elevated plasma levels of tumor necrosis
factor alpha [TNFα]), dyslipidemia, and reduced plasma levels of adiponectin. We report that
oral treatment of obese (fa/fa) rats with rimonabant (30 mg/kg) daily for 8 weeks abolished
hepatic steatosis. This treatment reduced hepatomegaly, reduced elevation of plasma levels …